1 February 2017 in Neurobiology of Disease
3 November 2026 in Clinical Cancer Research
Purpose: The Decipher Prostate Genomic Classifier (GC) and ArteraAI Multimodal Artificial Intelligence (MMAI) platform are widely used prognostic tools for localized prostate cancer, yet no direct comparison has been performed within the same patient cohort. Experimental Design: We sought to evaluate the concordance and prognostic value of GC and MMAI across multi-institutional cohorts totaling 688 patients with localized and oligometastatic prostate cancer. These included populations enriched for African American and East Asian patients. GC and MMAI scores were stratified into risk groups based on specimen type [biopsy or radical prostatectomy (RP)]. The primary endpoint was distant metastasis–free survival, measured from diagnosis to last follow-up or event. Results: GC and MMAI scores were significantly correlated across multiple cohorts. In Moffitt RP, biopsy, and National Cancer Centre Singapore cohorts, both MMAI and GC were prognostic alone and after adjusting for clinical variables. Multivariable analysis, including both biomarkers and clinical variables, showed that MMAI was significant even when accounting for GC in Moffitt RP and borderline in Moffitt biopsy. Analysis of concordant/discordant cases showed that patients who were high risk for both GC and MMAI did qualitatively worse. In pathway analysis, concordance with GC and MMAI was high for Moffitt RP and oligometastatic patients. Across both biopsy cohorts, although most biological pathways were concordant, there were consistent discordant signaling, metabolic, and DNA repair pathways. Conclusions: In the first direct patient-level comparison of GC and MMAI in prostate cancer, these biomarkers were found to demonstrate moderate correlation, and both biomarkers demonstrated prognostic value across diverse populations and disease states.
1 July 2026 in JNCI Cancer Spectrum
Background: While the ProtecT randomized trial demonstrated comparable oncologic outcomes between radical prostatectomy (RP) and radiation therapy (RT) for localized prostate cancer, several retrospective studies have reported mixed findings. In this study, we investigated whether nonrandomized studies tend to favor RP or RT and assessed whether the specialty of leading authors—urologists or radiation oncologists—correlates with study conclusions. Methods: We identified nonrandomized clinical studies published between 1993 and 2024 that compared RP and RT for localized prostate cancer and reported oncologic outcomes including biochemical, metastasis, and/or survival outcomes. Author specialty was determined based on whether the first and senior authors were affiliated with urology or radiation oncology departments. Studies in which a urologist and radiation oncologist were first and senior authors were excluded. Each study’s conclusion was categorized as favoring surgery, favoring radiation, or reporting no conclusive difference in oncologic outcomes. Multivariate logistic regression was used to evaluate predictors of study conclusions. Results: A total of 105 studies met inclusion criteria. Nearly half (44%) reported no conclusive difference in outcomes, while 42% favored RP and 14% favored RT. Multivariate analysis showed that use of national databases (p = 0.01) and urology author specialty (p = 0.01) predicted conclusions aligning with the author’s specialty. In a subgroup excluding studies relying solely on biochemical recurrence free survival outcomes, author specialty remained associated with conclusions, with urologists more likely to favor RP (p = 0.006). Conclusion: Author specialty was associated with the direction of study conclusions. Further research is needed to understand how these patterns may influence interpretation and decision-making in prostate cancer treatment.